skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: data de publicação: Após 2016 remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Weber, Jeffrey S ; Hodi, F Stephen ; Wolchok, Jedd D ; Topalian, Suzanne L ; Schadendorf, Dirk ; Larkin, James ; Sznol, Mario ; Long, Georgina V ; Li, Hewei ; Waxman, Ian M ; Jiang, Joel ; Robert, Caroline

Journal of clinical oncology, 2017-03, Vol.35 (7), p.785-792 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
2
The COVID-19 vaccine development landscape
The COVID-19 vaccine development landscape
Material Type:
Artigo 		Adicionar ao Meu Espaço

The COVID-19 vaccine development landscape

Thanh Le, Tung ; Andreadakis, Zacharias ; Kumar, Arun ; Gómez Román, Raúl ; Tollefsen, Stig ; Saville, Melanie ; Mayhew, Stephen

Nature reviews. Drug discovery, 2020-05, Vol.19 (5), p.305-306 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
3
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

Atkins, Johnique T ; George, Goldy C ; Hess, Kenneth ; Marcelo-Lewis, Kathrina L ; Yuan, Ying ; Borthakur, Gautam ; Khozin, Sean ; LoRusso, Patricia ; Hong, David S

British journal of cancer, 2020-11, Vol.123 (10), p.1496-1501 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
4
Embracing model-based designs for dose-finding trials
Embracing model-based designs for dose-finding trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Embracing model-based designs for dose-finding trials

Love, Sharon B ; Brown, Sarah ; Weir, Christopher J ; Harbron, Chris ; Yap, Christina ; Gaschler-Markefski, Birgit ; Matcham, James ; Caffrey, Louise ; McKevitt, Christopher ; Clive, Sally ; Craddock, Charlie ; Spicer, James ; Cornelius, Victoria

British journal of cancer, 2017-07, Vol.117 (3), p.332-339 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
5
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Material Type:
Artigo 		Adicionar ao Meu Espaço

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Owen, Dafydd R ; Allerton, Charlotte M N ; Anderson, Annaliesa S ; Aschenbrenner, Lisa ; Avery, Melissa ; Berritt, Simon ; Boras, Britton ; Cardin, Rhonda D ; Carlo, Anthony ; Coffman, Karen J ; Dantonio, Alyssa ; Di, Li ; Eng, Heather ; Ferre, RoseAnn ; Gajiwala, Ketan S ; Gibson, Scott A ; Greasley, Samantha E ; Hurst, Brett L ; Kadar, Eugene P ; Kalgutkar, Amit S ; Lee, Jack C ; Lee, Jisun ; Liu, Wei ; Mason, Stephen W ; Noell, Stephen ; Novak, Jonathan J ; Obach, R Scott ; Ogilvie, Kevin ; Patel, Nandini C ; Pettersson, Martin ; Rai, Devendra K ; Reese, Matthew R ; Sammons, Matthew F ; Sathish, Jean G ; Singh, Ravi Shankar P ; Steppan, Claire M ; Stewart, Al E ; Tuttle, Jamison B ; Updyke, Lawrence ; Verhoest, Patrick R ; Wei, Liuqing ; Yang, Qingyi ; Zhu, Yuao

Science (American Association for the Advancement of Science), 2021-12, Vol.374 (6575), p.1586-1593 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
6
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Nakajima, Erica C ; Drezner, Nicole ; Li, Xiaoxue ; Mishra-Kalyani, Pallavi S ; Liu, Yajun ; Zhao, Hong ; Bi, Youwei ; Liu, Jiang ; Rahman, Atiqur ; Wearne, Emily ; Ojofeitimi, Idara ; Hotaki, Lauren Tesh ; Spillman, Dianne ; Pazdur, Richard ; Beaver, Julia A ; Singh, Harpreet

Clinical cancer research, 2022-04, Vol.28 (8), p.1482-1486 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
7
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products
Material Type:
Artigo 		Adicionar ao Meu Espaço

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products

Gerven, Joop ; Bonelli, Milton

British journal of clinical pharmacology, 2018-07, Vol.84 (7), p.1401-1409 [Periódico revisado por pares]

England: John Wiley and Sons Inc

Texto completo disponível

Citações Citado por
8
Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding
Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding

Yan, F. ; Thall, P.F. ; Lu, K.H. ; Gilbert, M.R. ; Yuan, Y.

Annals of oncology, 2018-03, Vol.29 (3), p.694-699 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
Material Type:
Artigo 		Adicionar ao Meu Espaço

A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies

Zhou, Yanhong ; Lee, J. Jack ; Yuan, Ying

Statistics in medicine, 2019-12, Vol.38 (28), p.5299-5316 [Periódico revisado por pares]

England: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
10
Therapeutic Antisense Oligonucleotides Are Coming of Age
Therapeutic Antisense Oligonucleotides Are Coming of Age
Material Type:
Artigo 		Adicionar ao Meu Espaço

Therapeutic Antisense Oligonucleotides Are Coming of Age

Bennett, C. Frank

Annual review of medicine, 2019-01, Vol.70 (1), p.307-321 [Periódico revisado por pares]

United States: Annual Reviews

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (854)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (890)
  2. Web Resources  (1)
  3. Livros  (1)
  4. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2017  (1)
  2. 2017Até2017  (176)
  3. 2018Até2018  (132)
  4. 2019Até2020  (257)
  5. Após 2020  (328)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (890)
  2. Japonês  (83)
  3. Alemão  (2)
  4. Dinamarquês  (1)
  5. Chinês  (1)
  6. Francês  (1)
  7. Norueguês  (1)
  8. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.